Known as N-acetylcysteine-amide (NACA), the molecule is designed to slow vision loss by protecting retinal cells from oxidative stress. The Foundation Fighting Blindness is investing up to $7.5 million to advance the promising, emerging drug for retinitis pigmentosa, Usher syndrome, and related conditions.
Usher syndrome gene reviews trial#
The trial is for people with Usher syndrome. NACUITY CONDUCTING CLINICAL TRIAL FOR ORAL ANTIOXIDANT THERAPYĭallas-based Nacuity has launched a Phase 1/2 clinical trial in Australia for its oral antioxidant More than 100 patients are enrolled at approximately 20 sites in the US, Canada, and Europe. A major goal of the study, known as RUSH2A, is to better understand the course of vision loss in people with USH2A mutations, so that researchers can design successful clinical trials for potential therapies and identify patients for the treatment studies. The Foundation Fighting Blindness has launched a natural history study for people with mutations in the USH2A gene, which are leading causes of Usher syndrome and retinitis pigmentosa. The company has received authorization from the FDA to launch a Phase 1/2 clinical trial for people with retinitis pigmentosa.įOUNDATION FIGHTING BLINDNESS CONDUCTING RUSH2A NATURAL STUDY FOR PEOPLE WITH USH2A MUTATIONS RdCVF is naturally secreted by rods, the retinal cells that provide night and peripheral vision. Scientists demonstrated that RdCVF prevented or slowed the degeneration of cones, the cells in the retina that provide central and color vision and enable people to read, drive, and recognize faces. The emerging therapy performed well in several previous lab studies funded by the Foundation Fighting Blindness.
SPARINGVISION PLANS CLINICAL TRIAL TO EVALUATE SIGHT-SAVING PROTEIN FOR RPĪ spin-off of the Institut de la Vision, SparingVision, was established to clinically develop and commercialize a protein known as rod-derived cone-viability factor (RdCVF).
Vision and Eye Health Awareness Calendar.Virtual Workshop on Inflammation in Viral Gene Therapy of the Retina.Preclinical and Translational Research Webinar Series.Accessibility Statement, Tips & Guidelines.
0 kommentar(er)
